16. クロウ・深瀬症候群
[臨床試験数:12,薬物数:18(DrugBank:8),標的遺伝子数:5,標的パスウェイ数:79]
Searched query = "Crow-Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04396496 (ClinicalTrials.gov) | September 22, 2020 | 15/5/2020 | Treatment of POEMS Syndrome With Daratumumab | A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab | POEMS Syndrome | Drug: Daratumumab Injection | University of Arkansas | Janssen Scientific Affairs, LLC | Recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |
2 | NCT02921893 (ClinicalTrials.gov) | October 31, 2016 | 26/9/2016 | Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome | Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome | Plasmacytoma;POEMS Syndrome | Drug: Dexamethasone;Drug: Ixazomib Citrate;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Questionnaire Administration | Mayo Clinic | National Cancer Institute (NCI) | Recruiting | 18 Years | N/A | All | 34 | Phase 2 | United States |
3 | JPRN-jRCTs031180421 | 15/08/2016 | 25/03/2019 | LDCY-POEMS study | Phase II study of efficiency of peripheral blood stem cell harvest using low-dose cyclophosphamide plus G-CSF for POEMS syndrome | POEMS syndrome POEMS syndrome | Treatment by cyclophosphamide, mesna, graniserton, and lenograstim. Autologous peripheral blood stem cell harvest (auto-PBSCH) | Sakaida Emiko | NULL | Recruiting | >= 20age old | <= 70age old | Both | 14 | Phase 2 | Japan |
4 | JPRN-UMIN000018660 | 2015/08/17 | 17/08/2015 | Japanese POEMS syndrome with thalidmaide trial for compassionate use | Japanese POEMS syndrome with thalidmaide trial for compassionate use - Japanese POEMS syndrome with thalidmaide trial for compassionate use (JPOST15) | Crow-Fukase(POEMS) syndrome | FPF300 (thalidomide)100-300mg/day,at bedtime +Dexamethasone 20mg/day (day1-4) Duration:until the approval of thalidomide for POEMT syndrome | Chiba University Graduate School of Medicine | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan |
5 | JPRN-UMIN000018385 | 2015/07/01 | 22/07/2015 | Phase II study of efficiency of peripheral blood stem cell harvest in POEMS syndrome patients with low-dose cyclophosphamide plus G-CSF | POEMS syndrome | This study is composed of the following two steps of therapy. 1)PBSC mobilization using low dose cyclophosphamide and G-CSF 2)autologous peripheral stem cell transplantation after high dose chemotherapy | Chiba University HospitalDepartment of Hematology | NULL | Pending | 20years-old | 70years-old | Male and Female | 14 | Phase 2 | Japan | |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT02193698 (ClinicalTrials.gov) | July 2014 | 16/7/2014 | Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial | Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome | POEMS Syndrome | Drug: Lenalidomide+Dexamethasone | Chiba University | NULL | Completed | 20 Years | N/A | Both | 5 | Phase 2 | Japan |
7 | NCT01816620 (ClinicalTrials.gov) | March 2014 | 14/3/2013 | Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome | An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome | POEMS Syndrome | Drug: Lenalidomide, Dexamethasone | Peking Union Medical College Hospital | Celgene Corporation | Completed | 18 Years | N/A | All | 41 | Phase 2 | China |
8 | NCT01639898 (ClinicalTrials.gov) | July 2012 | 5/7/2012 | POEMS Syndrome Treatment With Lenalidomide | Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome. | POEMS Syndrome | Drug: Lenalidomide and dexamethasone | University Hospital, Limoges | Ministry of Health, France;Celgene Corporation | Completed | 18 Years | N/A | All | 51 | Phase 2 | France |
9 | JPRN-JMA-IIA00084 | 22/03/2012 | 19/03/2012 | Japanese POEMS Syndrome with Thalidomide Trial | Japanese POEMS Syndrome with Thalidomide Trial | Crow-Fukase (POEMS) syndrome | Intervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL. | J-POST Clinical Trial Office | Hokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima University | Completed | >=20 YEARS | No Limit | BOTH | 24 | Phase 3 | Japan |
10 | JPRN-JMA-IIA00046 | 13/09/2010 | 06/09/2010 | Japanese POEMS Syndrome with Thalidomide Trial | Thalidomide Treatment for Crow-Fukase (POEMS) Syndrome: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Extension Phase to Evaluate the Long-term Safety | Crow-Fukase (POEMS)syndrome | Intervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL. Control intervention1:FPF300 (placebo), Dose form:CAPSULE, Route of administration:ORAL. | J-POST Clinical Trial Office | Hokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima University | Completed | >=20 YEARS | No Limit | BOTH | 24 | Japan | |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | EUCTR2008-003202-33-IT (EUCTR) | 15/09/2009 | 17/11/2009 | Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002 | Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002 | POEMS SYNDROME MedDRA version: 9.1;Level: SOC;Classification code 10029205 | Trade Name: REVLIMID*21CPS 25MG INN or Proposed INN: Lenalidomide | ISTITUTO CLINICO HUMANITAS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
12 | NCT00971685 (ClinicalTrials.gov) | July 2009 | 3/9/2009 | The Treatment of Lenalidomide in Patients With POEMS Syndrome | Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome | POEMS Syndrome | Drug: Lenalidomide and dexamethasone | Istituto Clinico Humanitas | NULL | Recruiting | 18 Years | N/A | Both | 16 | Phase 2 | Italy |